News

Following the acquisition, Monistat will continue to be available through existing retail channels and will be marketed under Insight Pharmaceuticals growing portfolio of products. Insight Pharma CEO Gary

Relistor Subcutaneous Injection is indicated for the treatment for opioid-induced constipation (OIC) in patients with non-cancer pain. Salix Research and Development executive vice president and chief development officer

The primary goal of the study was to evaluate the safety and tolerability of two doses of Menerba, higher than those previously tested during the Phase 2 studies,

As per the terms of the deal, holders of Afexa common shares will receive C$0.71 in cash per common share. Valeant chairman and CEO Michael Pearson said Afexa’s

The trial aims to investigate each patient for toxicity, biochemical (Prostate Specific Antigen), radiographic and clinical responses. Previosly, APC-100 has been shown to have higher therapeutic activity than

T-614 is a novel disease modifying anti-rheumatic drug (DMARD) originally discovered by Toyama Chemical. Toyama Chemical and Eisai are jointly developing T-614 under a co-development and licensing deal

The company has posted a net loss of $3.31m for the second quarter of 2011, compared to $9.94m for the same period in 2010. inVentiv’s operating income was

As per the deal, the pharma firm is expected to continue to rely on Cegedim Relationship Management to supply thousands of users across all US field forces with

The drug is indicated for the treatment of seasonal allergies such as itchy nose and sneezing. The launching of the drug follows the US Food and Drug Administration